Viridian Therapeutics Gains as Fresh Analyst Coverage Adds to Recent Pipeline and Launch Momentum

Nov 19, 2026
viridian-therapeutics-gains-as-fresh-analyst-coverage-adds-to-recent-pipeline-and-launch-momentum

Viridian Therapeutics (VRDN) is up 4.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be fresh bullish analyst coverage on November 19, which added support to a stock that already had positive momentum from recent pipeline data and an encouraging commercial update. Recent interest has centered on the company’s thyroid eye disease franchise, early LUMVOA launch traction, and favorable Phase 1 results for VRDN-008.

Details:

  • Bank of America initiated coverage on Viridian with a Buy rating and a $47 price target on November 19, giving investors a new bullish reference point.
  • Viridian announced positive Phase 1 results for VRDN-008 on November 9, highlighting data that supported an every-8-week subcutaneous dosing profile.
  • The company’s third-quarter update showed $24.7 million in LUMVOA net product revenue, with more than 100 patients on therapy at the end of the quarter.
  • Viridian also remained active on the investor-conference circuit in mid-November, which may have helped keep attention on its commercial launch and broader autoimmune pipeline.
  • Sources:

    Viridian Therapeutics, SEC, Google Finance

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $VRDN Insider Trading Activity

    VRDN Insider Trades

    $VRDN insiders have traded $VRDN stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

    Here’s a breakdown of recent trading of $VRDN stock by insiders over the last 6 months:

    • JENNIFER TOUSIGNANT (Chief Legal Officer) has made 0 purchases and 2 sales selling 14,212 shares for an estimated $348,194.

    To track insider transactions, check out Quiver Quantitative’s insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    EARLY ACCESS

    Receive VRDN Data Alerts

    Real-time alerts on filings, insider trades, and market signals — before everyone else.

    Get Alerts →

    $VRDN Hedge Fund Activity

    We have seen 131 institutional investors add shares of $VRDN stock to their portfolio, and 123 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $VRDN Analyst Ratings

    Wall Street analysts have issued reports on $VRDN in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • B of A Securities issued a “Buy” rating on 11/19/2026
    • Wedbush issued a “Outperform” rating on 11/10/2026
    • Wells Fargo issued a “Overweight” rating on 11/10/2026
    • Leerink Partners issued a “Outperform” rating on 11/05/2026
    • RBC Capital issued a “Outperform” rating on 11/05/2026
    • Truist Securities issued a “Buy” rating on 11/05/2026
    • Evercore ISI Group issued a “Outperform” rating on 11/05/2026

    To track analyst ratings and price targets for $VRDN, check out Quiver Quantitative’s $VRDN forecast page.

    $VRDN Price Targets

    Multiple analysts have issued price targets for $VRDN recently. We have seen 9 analysts offer price targets for $VRDN in the last 6 months, with a median target of $41.0.

    Here are some recent targets:

    • Daniel Giraldo from B of A Securities set a target price of $47.0 on 11/19/2026
    • Laura Chico from Wedbush set a target price of $44.0 on 11/10/2026
    • Derek Archila from Wells Fargo set a target price of $39.0 on 11/10/2026
    • Thomas Smith from Leerink Partners set a target price of $54.0 on 11/05/2026
    • Lisa Walter from RBC Capital set a target price of $41.0 on 11/05/2026
    • Gregory Renza from Truist Securities set a target price of $42.0 on 11/05/2026
    • Maneka Mirchandaney from Evercore ISI Group set a target price of $33.0 on 11/05/2026

    This article is not financial advice. See Quiver Quantitative’s disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Leave a comment